SON-1010
Sonnet BioTherapeutics
[]
on tuesday at #aacr23, we ll be presenting the latest clinical data from our lead clinical candidate, son-1010, in a poster session. join us after for a webinar at 5 pm et as we discuss highlights from these results. #aacr23 #oncology #immunotherapy 
Experts in immune-oncology therapies developing proprietary FHAB™ (Fully Human Albumin Binding) technology. (NASDAQ: $SONN)